On Friday, Neogenomics Inc (NASDAQ: NEO) was -3.07% drop from the session before settling in for the closing price of $7.49. A 52-week range for NEO has been $6.08 – $19.11.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 39.30%. With a float of $126.92 million, this company’s outstanding shares have now reached $128.36 million.
Considering the fact that the conglomerate employs 2200 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 43.79%, operating margin of -13.06%, and the pretax margin is -11.7%.
Neogenomics Inc (NEO) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Neogenomics Inc stocks. The insider ownership of Neogenomics Inc is 1.38%, while institutional ownership is 98.83%. The most recent insider transaction that took place on May 27 ’25, was worth 38,000. In this transaction Director of this company bought 5,000 shares at a rate of $7.60, taking the stock ownership to the 5,000 shares. Before that another transaction happened on May 12 ’25, when Company’s Pres & Chief Operating Officer bought 5,700 for $8.58, making the entire transaction worth $48,895. This insider now owns 108,280 shares in total.
Neogenomics Inc (NEO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 39.30% per share during the next fiscal year.
Neogenomics Inc (NASDAQ: NEO) Trading Performance Indicators
You can see what Neogenomics Inc (NEO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach 0.30 in one year’s time.
Technical Analysis of Neogenomics Inc (NEO)
Compared to the last year’s volume of 1.81 million, its volume of 1.54 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 48.98%.
During the past 100 days, Neogenomics Inc’s (NEO) raw stochastic average was set at 16.34%, which indicates a significant decrease from 42.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.34 in the past 14 days, which was lower than the 0.59 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.49, while its 200-day Moving Average is $11.97. Nevertheless, the first resistance level for the watch stands at $7.43 in the near term. At $7.60, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.72. If the price goes on to break the first support level at $7.14, it is likely to go to the next support level at $7.02. Now, if the price goes above the second support level, the third support stands at $6.85.
Neogenomics Inc (NASDAQ: NEO) Key Stats
There are 128,695K outstanding shares of the company, which has a market capitalization of 934.32 million. As of now, sales total 660,570 K while income totals -78,730 K. Its latest quarter income was 168,040 K while its last quarter net income were -25,920 K.
